"Novo Nordisk Strikes Billion-Dollar Deals with Biotechs to Accelerate Obesity Drug Development"
TL;DR Summary
Novo Nordisk is expanding its obesity treatment portfolio by partnering with two Flagship Pioneering startups, Omega Therapeutics and Cellarity, to develop an mRNA-based obesity drug and a new medication for metabolic-associated fatty liver disease (MASH), respectively. These collaborations mark the first initiatives under a partnership agreement between Flagship and Novo Nordisk established in 2022.
Topics:business##biotechpartnerships#flagshippioneering#health-and-pharmaceuticals#mash#novonordisk#obesitydrug
- Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs STAT
- Novo Signs $1.1 Billion Obesity R&D Deals With Two Biotechs Yahoo Finance
- Omega Therapeutics stock more than doubles on Novo Nordisk obesity drug research pact MarketWatch
- Omega (NASDAQ:OMGA) Skyrockets After Research Deal With Novo Nordisk - TipRanks.com TipRanks
- Novo Nordisk signs deals worth up to $1bn with US biotechs in race for obesity drugs Financial Times
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
51%
111 → 54 words
Want the full story? Read the original article
Read on STAT